Immunotherapy after Chemo-Radiation shows promise for lung cancer

NCT ID NCT07050472

Completed Disease control Sponsor: Anhui Shi, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 45 patients with limited-stage small-cell lung cancer who received the immunotherapy drug durvalumab after standard chemoradiation. The goal was to see how long patients went without their cancer getting worse. Because this was a small, single-center review, the results are not definitive but provide real-world insight into this treatment approach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab (an immunotherapy drug)
What this could lead to: If results are positive, this could support using durvalumab after standard chemoradiation to help control limited-stage small-cell lung cancer longer.
What could go wrong: This is a small, single-center, retrospective study, not a large controlled trial. Results may not apply to all patients, and the drug can cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMALL CELL LUNG CANCER

Contacts and locations

Locations

Peking University Cancer Hospital and Institute

Beijing, Beijing Municipality, 100142, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.